Caixa Capital Risc, the venture capital arm of la Caixa, launched its new eight €20m fund.
Promoted along with CDTI and backed by public and private limited partners, Caixa Innvierte Start aims to invest in early stage companies with disruptive technologies originated from universities and research centers to validate their prototypes, build the team, and expand operations.
The fund will co-invest from €500k and €2m in each operation, along with other vc players.
With the new fund, Caixa Capital Risc now has €180 under management.
The first investment of the new fund is Aelix, a HIVACAT spin off dedicated to develop treatments against HIV/AIDS, which has just raised €11,5m from Ysios Capital, Caixa Capital Risc and Johnson & Johnson Innovation.
Led by Marcelino Armenter, president, Caixa Capital Risc has a portfolio 175 companies through 8 vehicles.